{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:23:53Z","timestamp":1789604633959,"version":"build-2803163510"},"reference-count":32,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2017,2,21]],"date-time":"2017-02-21T00:00:00Z","timestamp":1487635200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2017,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Primary hyperhidrosis is a condition characterized by excessive sweating. Patients are treated off\u2010license with oral anticholinergic medications and report adverse events associated with systemic anticholinergic interactions. This review assesses clinical evidence of efficacy, impact on quality of life and adverse events associated with oral anticholinergic therapy for primary hyperhidrosis. <jats:styled-content style=\"fixed-case\">PRISMA<\/jats:styled-content> guidelines were implemented to complete a systematic review (<jats:styled-content style=\"fixed-case\">PROSPERO<\/jats:styled-content>:<jats:styled-content style=\"fixed-case\">CRD<\/jats:styled-content>42016036326). <jats:styled-content style=\"fixed-case\">MEDLINE<\/jats:styled-content>,<jats:styled-content style=\"fixed-case\"> EMBASE<\/jats:styled-content> and PubMed were searched from 1946 to 2015. Inclusion criteria included observational and experimental studies, anticholinergic medication use in primary hyperhidrosis, oral therapy and clear diagnostic and outcome measures. Twenty\u2010three articles relevant to the inclusion criteria were analysed. Oxybutynin therapy improved symptoms in an average of 76.2% (range 60\u201397%) patients and improved <jats:styled-content style=\"fixed-case\">QOL<\/jats:styled-content> in 75.6% (range 57.6\u2013100%) of patients. Methantheline bromide therapy was associated with a 41% reduction in axillary sweating, 16.4% reduction in palmar sweating, 25% decrease in <jats:styled-content style=\"fixed-case\">HDSS<\/jats:styled-content> score and 40.9% increase in <jats:styled-content style=\"fixed-case\">DLQI<\/jats:styled-content> score. Outcome measures of glycopyrrolate therapy were too variable to collate. Dry mouth was reported in 73.4% (range 43.3\u2013100%) of participants taking oxybutynin 10 mg\/day, 38.6% (range 27.8\u201363.2%) of patients taking glycopyrrolate and 68.8% of patients taking methantheline bromide. Nine studies reported that patients stopped therapy due to adverse events. In eight of these studies, a mean of 10.9% of total participants ceased treatment due to dry mouth. Evidence of oral anticholinergic therapy for hyperhidrosis is limited. However, its use is associated with improvement in quality of life and clinical symptoms but at the cost of considerable adverse events.<\/jats:p>","DOI":"10.1111\/jdv.14081","type":"journal-article","created":{"date-parts":[[2016,12,15]],"date-time":"2016-12-15T18:24:37Z","timestamp":1481826277000},"page":"952-963","source":"Crossref","is-referenced-by-count":67,"title":["Treatment of primary hyperhidrosis with oral anticholinergic medications: a systematic review"],"prefix":"10.1111","volume":"31","author":[{"given":"L.","family":"Cruddas","sequence":"first","affiliation":[{"name":"University College London Medical School London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.M.","family":"Baker","sequence":"additional","affiliation":[{"name":"Department of Surgery Royal Free Hospital London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,2,21]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.02.038"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4725.2006.32334.x"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1590\/S1807-59322008000200006"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2011.04173.x"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.1040708"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/9780470712184"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2011.12.039"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10286-011-0128-4"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2012.05746.x"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0365-05962011000300005"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.6061\/clinics\/2014(09)06"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13973"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.142.8.1065"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.6061\/clinics\/2014(02)05"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2014.05.087"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ramb.2012.11.002"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1590\/S1679-45082014AO2841"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1590\/S1679-45082012000400002"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.avsg.2013.07.032"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/pde.12385"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10286-014-0264-8"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806-4841.20143272"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.07884.x"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.3344\/kjp.2012.25.1.28"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2011.01.023"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.3344\/kjp.2013.26.1.89"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.02.012"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/pde.12236"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2012.04708.x"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(00)01113-4"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200464080-00011"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.06.080"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.14081","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.14081","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T13:01:48Z","timestamp":1695042108000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.14081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,21]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["10.1111\/jdv.14081"],"URL":"https:\/\/doi.org\/10.1111\/jdv.14081","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,21]]}}}